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Abstract
 
The highly sensitive quantitation of virus-specific CD8
 
1
 
 T cells using major histocompatibility
complex–peptide tetramer assays has revealed higher levels of cytotoxic T lymphocytes (CTLs)
in acute and chronic virus infections than were recognized previously. However, studies in
lymphocytic choriomeningitis virus infection have shown that tetramer assays may include
measurement of a substantial number of tetramer-binding cells that are functionally inert. Such
phenotypically silent CTLs, which lack cytolytic function and do not produce interferon
(IFN)-
 
g
 
, have been hypothesized to explain the persistence of virus in the face of a quantita-
tively large immune response, particularly when CD4 help is impaired. In this study, we exam-
ined the role of functionally inert CTLs in chronic HIV infection. Subjects studied included
children and adults (
 
n 
 
5 
 
42) whose viral loads ranged from 
 
,
 
50 to 
 
.
 
100,000 RNA copies/ml
plasma. Tetramer assays were compared with three functional assays: enzyme-linked immuno-
spot (Elispot), intracellular cytokine staining, and precursor frequency (limiting dilution assay
[LDA]) cytotoxicity assays. Strong positive associations were observed between cell numbers
derived by the Elispot and the tetramer assay (
 
r 
 
5
 
 0.90). An even stronger association between
tetramer-derived numbers and intracellular cytokine staining for IFN-
 
g
 
 was present (
 
r
 
 
 
5
 
 0.97).
The majority (median 76%) of tetramer-binding cells were consistently detectable via intracel-
lular IFN-
 
g
 
 cytokine staining. Furthermore, modifications to the LDA, using a low input cell
number into each well, enabled LDAs to reach equivalence with the other methods of CTL
enumeration. These data together show that functionally inert CTLs do not play a significant
role in chronic pediatric or adult HIV infection.
Key words: peptide–major histocompatibility complex tetrameric complexes • intracellular 
cytokine staining • limiting dilution assays • enzyme-linked immunospot • CD8
 
1
 
 T cells
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Functionality of CTLs in HIV-infected Adults and Children
 
Introduction
 
The critical importance of HIV-specific cytotoxic T cells in
controlling virus replication and in determining the out-
come from infection has become increasingly apparent.
Earlier studies demonstrated that, in chronic infection, high
levels of CTLs were evident in asymptomatic subjects (1),
generally declining to undetectable with progression to dis-
ease (2). In acute infection, the timing of early control of
viremia was associated with the appearance of HIV-specific
CTLs (3, 4). More recently, utilization of peptide–MHC
tetramer assays (5) has shown a striking negative association
between CTL numbers and viral load in chronic HIV in-
fection (6), and has revealed by CD8
 
1
 
 T cell depletion
studies in acute and chronic simian immunodeficiency vi-
rus (SIV)
 
1
 
 infection in macaques the strong dependence on
virus-specific CTLs for virus control and protection against
rapid progression to disease (7, 8).
However, in spite of the quantitatively strong virus-spe-
cific CTL responses typically observed in chronic HIV in-
fection, ultimately control of virus replication is lost, for
reasons that remain unclear. Although the newer peptide–
MHC tetramer assays have allowed more precise enumera-
tion of the magnitude of the virus-specific CTL response,
in the lymphocytic choriomeningitis virus (LCMV) model,
the presence of significant numbers of phenotypically silent
CTLs, capable of binding tetramer but not of elaborating
effector functions, have now become apparent (9, 10). The
studies of chronic LCMV infection in CD4 knockout mice
may have particular relevance to HIV infection, in which
the dependence on virus-specific T helper responses in ad-
dition to CTLs for successful containment of virus has also
been clearly demonstrated (11–13). Although studies using
tetramers to quantitate CTLs in HIV infection have not
been compared with functional assays, similar investigations
in SIV infection have shown 50–500-fold higher numbers
of antigen-specific CTLs than are indicated by functional
assays (14). Thus, it may be hypothesized that, in the
context of impaired virus-specific T helper activity, func-
tionally inert CTLs may exist in HIV infection, and may
partially explain the paradox of a numerically strong HIV-
specific CTL response and yet the almost universal failure
to control viremia long term.
In this study of HIV-specific CTL activity, we address
the relationship between functional CTL activity and anti-
gen-specific CD8
 
1
 
 T cell numbers both in infected adults
and children. We reasoned that if phenotypically silent
CTLs were present in HIV infection, they would be most
evident either in pediatric infection, where viral loads tend
to be higher than in adult infection (15–17), disease pro-
gression is more rapid (18), and levels of functional CTLs
are reportedly lower (19, 20), or in adults with high viral
loads who simultaneously generated significant levels of
CTLs. Three functional assays were used to study a broad
 
range of subjects (
 
n 
 
5
 
 42) in order to compare the numbers
of functional CTLs present with the levels detectable by
peptide–MHC tetramers. The results of these studies show
that the most sensitive of the functional assays, intracellular
IFN-
 
g
 
 staining after stimulation with the appropriate pep-
tide, is equivalent to the tetramer assay in all subjects who
were investigated (
 
r 
 
5
 
 0.97, 
 
n 
 
5
 
 29). The majority (me-
dian of 76%) of tetramer-binding cells were detectable with
intracellular IFN-
 
g
 
 staining. The absence of phenotypically
silent CTLs was clear even in the antiretroviral therapy–
naive adults and children studied whose viral loads ex-
ceeded 100,000 RNA copies/ml plasma.
The least sensitive of the functional assays, the limiting
dilution assay (LDA) or precursor frequency assay, was in-
vestigated further to distinguish between the two major
possibilities that have been proposed to explain the well-
recognized low estimation of CTL numbers by these cyto-
toxicity assays (21–24). The first explanation is that a pro-
portion of tetramer-binding cells have a fundamental
inability to proliferate in culture to a level detectable in a
chromium release assay (25, 26). The second is that the in-
sensitivity of the LDA is principally due to competition
among different cells within the space of LDA wells, which
limits expansion of antigen-specific cells of interest to pro-
liferate to their true capacity (27, 28). The studies de-
scribed below indicate that modifications to the standard
LDA can raise the sensitivity of the LDA to approximate
that of the tetramer assay. The cause of CTL underestima-
tion by the LDA is therefore chiefly methodological and
not the consequence of substantial numbers of phenotypi-
cally silent CTLs.
 
Materials and Methods
 
Subjects Studied.
 
Samples of blood from 23 children and 19
adults infected with HIV-1 were studied (Tables I and II). All of
the children were perinatally infected and attend clinics at the
Boston Medical Center or the Children’s Hospital (Boston, MA),
except two (001-UNC and 002-UNC) from the University of
North Carolina (Chapel Hill, NC), one (VI06) from the Univer-
sity of Massachusetts (Amherst, MA), and one (DBN-11) from
the University of Natal (Durban, South Africa). The mean age of
the children was 8.8 yr, with a range of 3–17 yr. 21 of the 23
children and 3 of the 19 adults studied were treated with antiret-
roviral therapy. The viral loads in the children ranged from 
 
,
 
40
RNA copies/ml plasma to 867,724 copies/ml plasma (median
5,692 copies/ml). The CD4 percentage of total lymphocytes
ranged from 4 to 43% (median 28%). The viral loads in the adults
ranged from 
 
,
 
50 copies/ml to 
 
.
 
750,000 copies/ml (median
19,627 copies/ml). The CD4 percentage in the adults studied
ranged from 8 to 56% (median 30%). The adults studied all attend
clinics at the Massachusetts General Hospital except for one
(9354) who attended the Fenway Community Health Center
(Boston, MA), two attending King Edward VIII Hospital clinics
in Durban, South Africa (DBN-1 and DBN-12), and three (AA,
FWW, and SP) who attended the University of Texas South-
western Medical Center (Dallas, TX). All subjects tested were
chronically infected (
 
.
 
1 yr) except for adult subjects MCW and
 
1
 
Abbreviations used in this paper: 
 
CTLp, CTL precursor frequency; Elispot,
enzyme-linked immunospot; LCMV, lymphocytic choriomeningitis vi-
rus; LDA, limiting dilution assay; PFA, precursor frequency assay; SIV,
simian immunodeficiency virus. 
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GV, who were studied within 1 yr of presentation with acute
HIV syndrome.
 
LDAs.
 
LDAs were set up as described previously (29). In
brief, PBMCs were plated in 24 replicate wells at limiting dilu-
tion, ranging from 16,000 to 100 cells/well. A total of 0.73 
 
3 
 
10
 
6
 
PBMCs were required for each precursor frequency assay (PFA).
When cells numbers were limited (for 13 of the 54 PFAs per-
formed), between 50 and 100% of 0.73 
 
3 
 
10
 
6
 
 PBMCs were used
in the assay, with dilutions reduced proportionately. These effec-
tor cells were cultured with irradiated allogeneic feeder PBMCs
at 50,000 cells/well in a final volume per well of 200 
 
m
 
l of R10
medium (RPMI 1640, 10% FCS, and 10 mM Hepes buffer [all
from Sigma-Aldrich] with antibiotics). The anti-CD3 mAb,
12F6, was added at 10 
 
m
 
g/ml. On day 5 and once weekly there-
after, the medium was changed with R10 medium containing 50
U/ml of recombinant IL-2 (provided by Dr. M. Gately, Hoff-
mann-La Roche, Nutley, NJ). Wells were screened for specific
recognition of HLA-matched, peptide-pulsed, 
 
51
 
Cr (New En-
gland Nuclear)-labeled EBV-transformed B lymphoblastoid cell
line (BCL) target cells as described previously (29) after 15–25 d
in culture.
Calculation of CTL precursor frequency (CTLp) was per-
formed using the maximum likelihood method (28) using a statis-
tical program written by S.A. Kalams. Wells that showed 10% or
greater specific lysis were scored as positive, as per convention.
Comparison was made of lysis of peptide-pulsed target cells and
 
Table I.
 
Clinical, Immunological, and Virologic Details of the 20 Pediatric and 10 Adult Subjects Studied by LDA, Elispot, and Tetramer 
Assays Shown in Fig. 2, A–C
 
Subject
Years
HIV infected Viral load
Antiretroviral
therapy CD4
 
1
 
 T cells
 
RNA copies/ml plasma cells/mm
 
3
 
%
 
Pediatric subjects:
all infected perinatally
UNC-001 11 595,827 Nil 122 4
UNC-002 17
 
,
 
400 Mono 462 22
004-BMC 10 2,274 Dual 868 34
005-BMC 10 35,040 Dual 444 21
007-BMC 9
 
,
 
50 Dual 672 26
009-BMC 9 3,329 Quad 161 15
018-BMC 10 4,457 Dual 980 43
021-BMC 14 11,849 Dual 650 16
026-BMC 9 1,261 Dual 681 36
014-TCH 9 15,449 Dual 352 36
016-TCH 4
 
,
 
40 Dual 1,911 37
027-TCH 9 9,219 Dual 1,460 41
032-TCH 7 15,873 Mono 472 25
034-TCH 7 26,100 Dual 957 22
036-TCH 14 2,931 Mono 616 23
040-TCH 12 1,846 Mono 1,080 30
044-TCH 8 8,195 Naive 902 35
048-TCH 7 6,827 Triple 983 36
049-TCH 4 62,833 Dual 1,092 40
VI06 3 8,978 Triple 1,336 32
Adult subjects WB
 
,
 
1
 
,
 
50 Triple 477 36
ESJ
 
,
 
1
 
,
 
50 Triple 946 47
9354
 
.
 
13 147,000 Naive 180 8
161j 21
 
,
 
50 Naive 670 41
661 NK 4,100 Naive 1,344 47
115i
 
.
 
13 35,000 Naive 398 18
11324 NA 67,000 Naive 466 NA
199pg
 
.
 
11 3,700 Naive 810 32
11504 NA 155,000 Naive 601 NA
221-1
 
.
 
15 221,000 Naive 894 30
Antiretroviral therapy designated as follows: Naive; Nil (previously on therapy but taking no therapy when studied); Mono, monotherapy; Dual, two
drugs; Triple, three drugs; Quad, four drugs. NK, date of infection not known; NA, not available. 
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lysis of control target cells that had not been pulsed with peptide.
The fraction of negative wells at a given input cell number show-
ing 
 
,
 
10% lysis of peptide-pulsed targets was subtracted from the
fraction of negative wells showing 
 
,
 
10% lysis of control targets.
To perform the calculation of CTL frequency at each individ-
ual seeding set of 24 replicate wells, the identical assumptions
were made, which include the premise that the number of spe-
cific CTLs of interest are distributed in the LDA wells according
to the Poisson distribution (28). In this case, if the CTL fre-
quency is 
 
z
 
, the expected fraction of LDA wells containing at
least one of the specific CTLs would be   where 
 
x
 
 is
the number of cells per well at that particular seeding. From this
1e
zx – – () ,
 
Table II.
 
Clinical, Immunological, and Virologic Details of the 5 Pediatric and 17 Adult Subjects Studied by Tetramer and Intracellular IFN-
 
g
 
 
Staining Assay as Shown in Figs. 2 D and 3
 
Group Subject
CTL
specificity
Tetramer
staining
(/CD8
 
1
 
)
ICS
(/CD8
 
1
 
)
Ratio
ICS/tetramer
Time
HIV
infected Viral load ART
Duration of
ART
regimen
CD4
 
1
 
T cells
p24
Gag-specific
T helper
response
(IFN-
 
g
 
 ICS/
CD4
 
1
 
)
 
%% % y r
RNA copies/
ml plasma yr cells/mm
 
3
 
%%
 
Group
 
 
 
A
 
*
 
DBN-11
 
‡
 
B42 Gag 3.31 3.45 104 4 867,724 Naive
 
2
 
277 15 0.00
DBN-12 B42 Gag 0.59 0.24 41
 
.
 
4 NA Naive
 
2
 
433 13 0.03
9354 A2 Gag 1.88 1.44 77
 
.
 
13 147,000 Naive
 
2
 
180 8 0.00
115i A2 Gag 0.33 0.19 58
 
.
 
13 35,000 Naive
 
2
 
398 18 0.00
63g A2 Gag 0.85 0.66 78 10 20,800 Naive
 
2
 
375 17 ND
2211 A2 Gag 0.31 0.27 87
 
.
 
15 175,000 Naive
 
2
 
723 29 0.00
Group B
 
§
 
DBN-1 B42 Gag 3.12 1.93 63 1 1,364 Naive
 
2
 
1,027 56 0.18
021-BMC
 
‡
 
B42 Gag 3.52 1.83 52 14 11,849 Dual 3 650 16 ND
026-BMC
 
‡
 
B42 Gag 1.79 1.28 72 9 1,261 Dual 3 681 36 0.12
032-BMC
 
‡
 
B42 Gag 2.33 1.89 81 8 1,436 Triple 3 538 24 0.00
SP B8 Gag 0.10 0.04 40 NK 26,037 Naive 2 516 30 0.04
SP B8 Nef 1.79 1.26 70
FWW B8 Gag 1.49 1.40 94 .4 19,627 Naive 2 506 24 0.01
FWW B8 Nef 0.24 0.23 96
MCW B8 Gag 0.17 0.19 112 ,1 .750,000 Naive 2 488 28 ND
MCW B8 Nef 1.15 0.88 77
GV B8 Nef 0.43 0.27 63 ,1 111,000 Nil 0.1 970 32 ND
AA A2 Gag 0.73 0.67 92 .3 ,50 Triple 0.3 267 23 ND
161j A2 Gag 1.43 0.57 40 21 ,50 Naive 2 670 41 5.80
661 A2 Gag 0.76 0.63 83 NK 4,100 Naive 2 1,344 47 ND
199pg A2 Gag 0.49 0.31 63 .11 3,700 Naive 2 811 27 0.13
JFM A2 Gag 0.17 0.13 76 2 307 Nil 0.3 555 38 0.07
BNN-06 A2 Gag 0.22 0.16 73 11 2,000 Naive 11 NA NA 0.03
Group Ci 019-BMC‡ A2 CMV 0.67 0.48 72 7 26,366 Dual 3 1,148 24 0.40
009-BMC‡ A2 CMV 1.22 1.22 100 10 3,329 Quad 1 161 15 0.02
AA A2 CMV 1.07 0.90 84 .3 ,400 Triple 0.3 267 38 ND
SI A2 CMV 0.17 0.13 76 HIV2 222 2 2 2
PG B7 EBV 0.26 0.18 69 HIV2 222 2 2 2
A2 EBV 3.01 2.92 97
Antiretroviral therapy designated as follows: Naive; Nil (previously on therapy but taking no therapy when studied); Mono, monotherapy; Dual, two
drugs; Triple, three drugs; Quad, four drugs. ICS, intracellular IFN-g staining; ART, antiretroviral therapy; NA, coincident data unavailable; NK,
duration of infection not known.
*Known infected .4 yr, ART naive, viral load .20,000.
‡Perinatally infected pediatric subjects.
§Comparison between tetramer and ICS in PBMCs from a broad range of HIV-infected subjects as shown.
iComparison of tetramer and ICS in EBV- and CMV-specific responses.1823 Goulder et al.
can be derived the formula for the most likely estimate for the
CTL frequency, f, which is   where y is the frac-
tion of wells scoring negative in the LDA. To convert this ex-
pression into log10 values, as LDA data have conventionally been
presented (for example as in Fig. 1 A), this approximates (as ln
0.368 5 21.00) to   Thus from this ex-
pression can be derived the more familiar fact that when the frac-
tion of wells scoring negative in the LDA, y, is 37%, the best esti-
mate of CTL frequency is the reciprocal of the number of cells
per well at that seeding, x.
In the 50 comparisons of percentage of tetramer-binding cells
and percentage of specific lysis in the LDA wells, the specific ef-
fector to target ratio was not determined for each LDA well, in
addition to measuring tetramer staining. However, the cell num-
bers in the eight wells that were counted were similar (Table III).
Enzyme-linked Immunospot Assays. Fresh PBMCs were plated
in 96-well polyvinylidene plates (Millipore) that had been pre-
coated with 0.5 mg/ml anti–IFN-g mAb, 1-DIK (Mabtech). The
peptides were added in a volume of 20 ml and then PBMCs were
added at 50,000 cells/well in a volume of 180 ml. The end con-
centration of the peptides was 10 mM. The plates were incubated
overnight at 378C, 5% CO2, and washed with PBS before addi-
tion of the second, biotinylated anti–IFN-g mAb, 7-B6-1 biotin
(Mabtech) at 0.5 mg/ml and incubated at room temperature for
100 min. After washing, streptavidin-conjugated alkaline phos-
phatase (Mabtech) was added at room temperature for 40 min.
Individual cytokine-producing cells were detected as dark spots
after a 20-min reaction with 5-bromo-4-chloro-3-indolyl phos-
phate and nitro blue tetrazolium using an alkaline phosphatase–
conjugate substrate (Bio-Rad Laboratories). The number of spe-
cific T cells was calculated by subtracting the negative control
values. The background was ,40/106 PBMCs (2 spots/well at
50,000 PBMCs/well) in all cases. Wells which contained .50
spots were not used for accurate quantification. Assays were re-
f y ln () x ¤ , – () =
f y log () x 0.37 log () ¤ . =
peated using lower input numbers of cells as necessary and in
quadruplicate in order to quantitate responses to individual pep-
tides more accurately.
Intracellular INF-g Staining. Intracellular cytokine staining as-
says were performed as described elsewhere (30, 31). In brief,
0.2–1.0 3 106 PBMCs were incubated with 4 mM peptide and 1
mg/ml each of the mAbs anti-CD28 and anti-CD49d (Becton
Dickinson) at 378C, 5% CO2 for 1 h, before the addition of 10
mg/ml of brefeldin A (Sigma-Aldrich). After an additional 6-h
incubation at 378C, 5% CO2, the cells were placed at 48C over-
night. PBMCs were then washed and stained with surface Abs
anti-CD8 and anti-CD3 (Becton Dickinson) at 48C for 20 min.
PBMCs which were stained also with tetramers were incubated
with the tetramer at 48C for 30 min before the addition of the
surface Abs. After washing, the PBMCs were then fixed and per-
meabilized (Caltag) and anti–IFN-g mAb was added (Becton
Dickinson). Cells were then washed and analyzed.
Peptide–MHC Tetramer Assays. Peptide–MHC tetramers
were synthesized as described previously (5, 32). The tetramers
used in these studies were the HLA-A*0201-SLYNTVATL (A2
Gag [5, 33–35]), A*0201-NLVPMVATV (A2 CMV [36]),
A*0201-GLCTLVAML (A2 EBV [37]), B7-RPPIFIRRL (B7
EBV [38]), B8-FLKEKGGL and B8-EIYKRWII (B8 Nef and
Gag [32, 35, 39]), and B42-TPQDLNTML (B42 Gag [35, 40])
complexes. The B7-expressing plasmid was provided by Dr. G.
Gillespie (University of Oxford, Oxford, UK). The B42-express-
ing plasmid was obtained by site-directed mutagenesis of the B7-
expressing plasmid (Stratagene [40]). HLA heavy chain was ex-
pressed in Escherichia coli with an engineered COOH-terminal
signal sequence containing a biotinylation site for the enzyme
BirA. After refolding of heavy chain, b2m and peptide, the com-
plex was biotinylated by BirA (Avidity) in the presence of ATP-
Mg21 (Sigma-Aldrich). After purification by gel filtration and an-
ion exchange chromatography, tetramer formation was induced
by the addition of streptavidin. Use of phycoerythrin-labeled
streptavidin enabled antigen-specific cells to be visualized by flow
cytometry.
Staining of lymphocytes was performed by incubating 0.5 3
106 PBMCs for 30 min at 48C with the appropriate tetramer at
0.5 mg/ml of tetramer, then for an additional 20 min with satu-
rating amounts of peridinine chlorophyll protein–conjugated
anti-CD8 mAb and allophycocyanin-conjugated anti-CD4 mAb
(Becton Dickinson). Stained samples were analyzed on a FACS-
Calibur™ flow cytometer using CELLQuest™ software (Becton
Dickinson). Control samples for the tetramer staining were
PBMCs from HLA-mismatched HIV-infected persons. Quadrant
boundaries for tetramer staining were established by exclusion of
.99.97% of control CD81 T cells.
Results
Comparison of LDA, Enzyme-linked Immunospot, and
Tetramer Assay to Quantify CTL Numbers. To determine
whether higher numbers of HIV-specific CTLs were de-
tectable by tetramer assays compared with functional assays,
as has been demonstrated in relation to other virus-specific
CTLs (14, 22–24), initial studies were performed to com-
pare the LDA with the tetramer assay. An example of data
from one subject is shown in Fig. 1, A and B. Similar assays
performed on a total of 20 subjects (13 children and 7
adults; a median of two comparisons per subject) are com-
piled in Fig. 2 A. CTL numbers were underestimated by
Table III. Comparison of the Cellular Composition of Eight PFA 
Wells 15 and 21 d after Culture
Assay day 15 Assay day 21
Well
Tetramer
staining CD8 Cells/well
Tetramer
staining CD8 Cells/well
%% n %% n
1 0.21 74 210,000 4.75 80 219,000
4 0.28 85 241,000 0.84 90 205,000
5 0.03 88 171,000 0.55 91 240,000
6 0.11 92 241,000 1.16 93 185,000
7 4.02 67 257,000 3.01 71 66,000
9 0.57 82 256,000 5.20 90 201,000
10 0.46 66 280,000 0.50 81 223,000
11 0.47 88 241,000 2.75 92 247,000
Mean 0.47 80 237,000 2.34 86 198,000
Wells analyzed were from adult subject 161j, as described in the legend
to Fig. 4. Input cell number of the cells analyzed was 440 cells/well.
A*0201-SLYNTVATL tetramer staining of PBMCs was 2.0%. For the
chromium release assay performed on day 15, 45% of the cells in each
well were removed; a further 20% were removed for tetramer staining
on day 16.1824 Functionality of CTLs in HIV-infected Adults and Children
the LDA compared with tetramer staining by a factor of 14,
comparing median values. When stratified by age, the LDA
compared with tetramer underestimated by a factor of 14 in
adults (adult data: r 5 0.71, P , 0.001; t test), and by a fac-
tor of 17 in children (pediatric data: r 5 0.67, P , 0.001).
Estimates of antigen-specific cells were also made using a
second functional assay, detection of IFN-g production
after peptide stimulation in enzyme-linked immunospot
(Elispot) assays (Fig. 1 C). Comparison of these assays dem-
onstrated a very strong association (r 5 0.90, P , 0.001;
Fig. 2 B), with tetramer assays detecting only a 3.5-fold
greater number of antigen-specific cells than the Elispot as-
say, comparing median values. These data suggest that at
least 25–30% of the tetramer-binding cells are functional,
to the extent of elaborating IFN-g in response to specific
antigen. The data regarding cytotoxic function of tetramer-
Figure 1. Illustration of methods of CTL enumeration. The subject studied was 9354 (HLA-A*0201/3 B7/35 Cw4/7); response shown: A*0201-
SLYNTVATL (p17 Gag, residues 77–85; reference 32). (A) Precursor frequency assay (LDA). The target cells were HLA-A*0201–matched EBV-trans-
formed B cells. (B) Tetramer assay, showing staining of the same PBMCs used in A. (C) Elispot assay, using the same PBMCs used in A and B. CTL enu-
meration was calculated from wells that contained ,50 spots, i.e., at 7,600 PBMCs/well and 4,400 PBMCs/well. Standard deviation from the mean is
shown from the estimated CTL frequency of 6,060/106 PBMCs. sfc, spot-forming cell.
Figure 2. Comparison of LDA, Elispot, intracellular IFN-g
staining, and tetramer assays. (A) Comparison of LDA and
tetramer assays. 54 comparisons are shown, 27 from pediatric
samples (h), 27 from adult samples (i). The correlation co-
efficient for pediatric samples and adult samples analyzed sep-
arately was 0.67 and 0.74, respectively. The lower limit of
detection for the LDA used was 10 cells/106 PBMCs. (B)
Comparison of Elispot and tetramer assays. 19 comparisons
are shown, 4 from adult samples and 15 from pediatric sam-
ples. The correlation coefficient for pediatric samples and
adult samples analyzed separately was 0.87 and 0.97, respec-
tively. The lower limit of detection for each assay used was
100 cells/106 PBMCs. sfc, spot-forming cell. (C) Compari-
son of LDA and Elispot assays. 30 comparisons are shown,
21 from pediatric samples, 9 from adult samples. Correlation
coefficient for pediatric samples and adult samples analyzed
separately was 0.46 and 0.44, respectively. (D) Comparison
of tetramer and intracellular IFN-g staining assays. Compari-
sons of HIV-specific responses in subjects infected .2 yr and
viral loads .20,000 copies/ml plasma are shown by black
filled squares; remaining comparisons of HIV-specific re-
sponses are shown by open squares; CMV- and EBV-specific
responses are shown by gray filled squares.1825 Goulder et al.
binding cells suggest that at least 5–10% of tetramer-bind-
ing cells are capable of lysing target cells expressing the ap-
propriate antigen. However, if there are methodological
shortcomings underlying one or both of the LDA and
Elispot assays, these estimates of CTL functionality may be
grossly inaccurate. The relatively poor correlation between
the two functional assays of antigen-specific CTLs (Fig. 2
C) suggests that this is indeed the case. The degree of preci-
sion of the LDA and the Elispot assays was therefore ex-
plored further.
Comparison of CTL Numbers Derived from Tetramer and In-
tracellular Cytokine Staining. These results from studying
persons with chronic HIV infection, as well as data from
similar comparisons made in subjects with chronic EBV in-
fection (24), show that the Elispot assay consistently esti-
mates antigen-specific CD81 T cell numbers as 25–30% of
the figures derived from tetramer staining (Fig. 2 B). One
explanation for these differences would be that there is a
large fraction of tetramer-positive cells that are incapable of
producing IFN-g, and are therefore functionally inert. A
second possibility would be that the Elispot assay is simply
less sensitive than a flow-based assay, and therefore some
IFN-g–producing cells are below the Elispot detection
limit. To differentiate between these possibilities, the
Elispot assay was modified to allow quantification by flow
cytometry. A comparison was made between the number
of cells that could bind tetramer and the number of pep-
tide-stimulated cells detectable by intracellular IFN-g stain-
ing using flow cytometry.
In 29 direct comparisons (Table II), the number of CTLs
by intracellular IFN-g staining was a median of 76% of the
number of CTLs estimated by tetramer staining (range 40–
112%; r 5 0.97, P , 0.001; Fig. 2 D). Not shown are 15
additional comparisons that were undertaken using PBMCs
from HIV-infected persons in which responses were unde-
tectable (,0.03% of CD81 T cells) by either assay. These
data also included six comparisons using EBV- and CMV-
specific tetramers (gray symbols in Fig. 2 D). Analyzing
only the comparisons using HIV-specific tetramers, the
correlation coefficient was virtually unaltered (r 5 0.96).
As one might be more likely to find nonfunctional
CD81 T cells in subjects not on antiretroviral therapy who
had been persistently exposed to high levels of viremia, six
subjects defined in this study as such were also analyzed
Figure 3. Representative
comparisons of tetramer staining
(A–D) and intracellular IFN-g
staining after peptide stimulation
(E–H) and after p24 Gag antigen
(Ag) stimulation (I–L) in four
subjects described in Table II.
(A–D) Staining by tetramers of
PBMCs that had been stimulated
with no antigen. Levels of stain-
ing expressed as percentage of
CD81 T cells. (E–H) Intracellu-
lar IFN-g staining after stimula-
tion with the peptide corre-
sponding with the tetramer in
the respective panels A–D. Lev-
els of staining expressed as per-
centage of CD81 T cells. (I–L)
Intracellular IFN-g staining after
stimulation with p24 antigen.
Levels expressed as percentage of
CD41 T cells. In all panels, lym-
phocyte boundaries were deter-
mined by exclusion of 99.97% of
control lymphocytes.1826 Functionality of CTLs in HIV-infected Adults and Children
separately (shown by filled symbols; Fig. 2 D), again with
an unaltered correlation coefficient (r 5 0.97) between tet-
ramer-binding cells and IFN-g–producing cells. (These six
subjects were defined as such using the following conserva-
tive criteria: known to have been infected .4 yr; viral load
.20,000/ml plasma; and antiretroviral therapy naive.)
Thus, even for subjects such as 9354, whose absolute CD4
count had declined over 11 yr from 1988 to 1998 from
853/mm3 to 180/mm3, and who was studied at the 12/98
time point at which his viral load was greatest (147,000
copies/ml plasma) before starting antiretroviral therapy,
there remained clear evidence of substantial functional ac-
tivity of CD81 T cells in response to peptide stimulation
(Fig. 3). This assay was performed three times using differ-
ent aliquots of PBMCs cryopreserved from the same time
point with very similar results: the proportion of tetramer-
binding cells detectable by intracellular IFN-g staining was
65, 76, and 77%, respectively (Fig. 3, and data not shown).
Similarly, all PBMCs from a 4-yr-old child, DBN-11 (viral
load 867,000), that bound the B42-Gag tetramer appeared
to be functional by the intracellular IFN-g staining assay
(Fig. 3). These data support the evidence from comparisons
of Elispot assays and tetramer assays (Fig. 2 C) that the great
majority of HIV-specific CTLs that bind tetramer are also
functional, and can be detectable by flow-based assays that
measure intracellular IFN-g production in response to pep-
tide stimulation. By comparison, in the description of Db-
GP33–specific CTL activity in the CD4 knockout mice
chronically infected with LCMV (10), .98% of cells that
were capable of binding the corresponding tetramer were
nonfunctional.
To address the question of whether the chronically in-
fected subjects described above with persistently high viral
loads might nonetheless still be able to generate HIV-spe-
cific T helper responses, the identical intracellular IFN-g
assay was used to measure responses to p24 Gag antigen.
Consistent with previous studies of Gag-specific T helper
responses in HIV infection (11, 30), p24 Gag–specific T
helper activity was either undetectable or extremely weak
in subjects with high viral loads, and only high in persons
with low viral loads (Table II and Fig. 3).
Analysis of Antigen-specific T Cells within the LDA Wells
Using Tetramers. The cytotoxic functionality of tetramer-
binding cells was next investigated further. To determine
whether a factor contributing to underestimation of CTL
numbers by LDAs was the presence of antigen-specific
CD81 T cells that were detectable by tetramer, mostly able
to elaborate IFN-g, but incapable of cytotoxic function,
comparison of the percentage of specific lysis observed in
the chromium release assay, and the level of tetramer stain-
ing in each well on the same day of chromium release assay
was made for each of 50 wells. This revealed a strong cor-
relation (r 5 0.79, P , 0.001) between specific lysis ob-
served in each well and the level of tetramer-staining cells
present in the well (50 wells tested; Fig. 4). This correlation
demonstrates the absence of wells that contained tetramer-
binding cells but without the corresponding degree of cy-
totoxicity.
Tetramer staining of the 33 “negative” LDA wells (that
is, those that scored ,10% specific lysis) revealed that 19 of
these wells in fact contained antigen-specific CD81 T cells
(Fig. 4). Whereas only 17 of the wells that were analyzed
registered as positive in the LDA chromium release assay,
36 of the wells contained A*0201-SL9–specific CTLs when
assayed by tetramer. Thus, it is clear that a substantial num-
ber of A*0201-SL9–specific CTLs are present in the LDA
wells and are not detected in the chromium release assay, as
the threshold for detection by the cytotoxicity assay is set at
10%. This relatively high cutoff has been conventionally
accepted to maintain the specificity of the cytotoxicity as-
say, but the downside is a loss in sensitivity.
To determine the stability of the proportion of tetramer-
staining cells within LDA wells over time, eight of the
wells that were analyzed after 15 d of culture were reana-
lyzed 6 d later. Some of these wells showed marked
changes in the cellular composition between days 15 and
21 (Table III). Although the proportion of CD81 cells in
the wells had increased only modestly (a 1.5-fold increase)
in this short time, absolute numbers of tetramer-staining
cells in some wells increased up to 24-fold (well 1), and in
one case decreased by .40% (well 5). Thus, it is clear that
antigen-specific (tetramer-staining) cells within the LDA
assay wells can increase with longer in vitro culture, but
also can be overgrown by cells that do not stain with that
tetramer.
Figure 4. Tetramer staining by the A*0201-SLYNTVATL tetramer of
cells after 16 d in culture in 50 PFA wells, measured against specific lysis
in the chromium release assay performed the previous day. 25 wells were
from one PFA using cells from adult subject 161j (A*0201-positive); 25
wells were from a separate PFA from pediatric subject 048-TCH
(A*0201-positive). Lymphocytes in control wells cultured for the same
length of time (16 d) were from pediatric subject 049-TCH (A*0201-
negative), and ,0.02% stained with the tetramer. Dashed lines show the
threshold for positivity of the wells by the chromium release assay (10%
or more specific lysis) and for the tetramer staining (.0.02% of all gated
lymphocytes in the well). Inset shows the number of wells that were pos-
itive by chromium release assay but negative by tetramer staining (0), the
number positive by both (17), etc. Thus, of the 50 wells analyzed, 19
contained tetramer-binding cells but did not score positive in the chro-
mium release assay.1827 Goulder et al.
CTL Frequency Estimation by LDA Using Low Numbers of
Input Cells per Well. From the data described above, it
was hypothesized that a major cause of the underestimate
of CTL numbers by the LDA is overgrowth of specific ef-
fectors by other cells. To test this hypothesis, it was rea-
soned that LDA wells that started with a low input cell
number would be less likely to be overgrown, and should
provide a closer estimate of the true CTL frequency. To
calculate the CTLp at each individual replicate set of cell
seedings, as opposed to from the standard seven dilutions,
the identical assumptions are made, including that CTLs are
distributed in the LDA wells according to the Poisson dis-
tribution (see Materials and Methods). From this assump-
tion, and knowing both the fraction of wells scoring “nega-
tive” in the LDA for a particular replicate set of cell
seedings and the input number of cells used to seed each
well, the best estimate of the CTLp can be made for each of
the seven dilutions of the LDA and compared with the
standard estimate derived from all seven calculations to-
gether. In the four sets of assays performed in this way, the
LDA using low input cell number per well (10–40 cells/
well) provided a very close approximation to the tetramer
or Elispot-derived estimate of CTL numbers (32, 37, 41;
Table IV).
We therefore reevaluated standard LDAs from these do-
nors to determine whether there is a negative association
between input cell number per well and CTLp estimate.
Performing these calculations in each of five LDAs (PB-
MCs from two donors) showed a clear negative association
between CTLp estimate and input cell number per well,
overall with a correlation coefficient of r . 0.80 in each
case (three replicate LDAs using PBMCs from one donor
are shown in Fig. 5, A–C). In Fig. 5 C the estimates of
CTL frequency from input cell numbers of ,50 cells/well
Table IV. Estimation of CTL Frequency Using Low Input Cell 
Numbers per Well
LDA
Subject Date
Standard
seven
dilution
LDA
100
cells/
well
40–50
cells/
well
10–25
cells/
well Elispot Tetramer
016-TCH 8/99 703 4,893 5,103 11,883 2,400 10,200
021-BMC 9/99 ND 5,579 5,555 12,502 2,700 5,500
199-pg 10/99 371 ND 2,078 5,500 5,646 5,700*
016-TCH 11/99 ND 7,519 8,701 11,321 ND 7,400
Data shown as CTLs/106 PBMCs. For 199pg, the value of 371/106
PBMCs as the estimated CTLp by standard seven dilution LDA is the
mean of the three CTLp estimates of 536, 329, and 248/106 PBMCs that
were shown in Fig. 5, A–C. The responses studied for donors 016-TCH
and 021-BMC were to the B42-restricted epitope TPQDLNTML (p24
Gag residues 48–56 [references 32, 37]) and for donor 199pg was to the
A*3002-restricted epitope RSLYNTVATLY (p17 Gag residues 76–86
[reference 41]). For 016-TCH 8/99, 021-BMC 9/99, and 199pg (see
Fig. 5), 320 replicate wells at each input cell number shown were
analyzed. For 016-TCH 11/99, using a PBMC sample from 11/99, 96
replicate wells at each input cell number per well shown were analyzed.
*Intracellular IFN-g–staining cells.
Figure 5. Comparison of three LDAs set up simultaneously from the same donor (adult
199pg: HLA-A*0201/*3002 B44/51 Cw5/7) showing the estimated frequency of CTLs by
analysis of individual 24-well replicates. Elispot-derived CTL frequency was 5,646/106 PB-
MCs. (A and B) Assays shown were performed after 16 d of culture. Peptide: RSLYNT-
VATLY (p17 Gag, residues 76–86; references 32, 41); target cells: EBV-522 (A*3002/2
B*1402/2 Cw*0802) were matched only through A*3002 with the effectors. LDA estimates
were 536 and 329/106 PBMCs in A and B, respectively. (C) Assays in C were performed after
22 d of culture. LDA estimate was 248/106 PBMCs. Estimations of CTL frequency using
200, 40, and 10 cells/well used 320 replicate wells in each case. Estimate of CTL frequency
from the 24-well replicates of 8,000 cells/well was not done, as the fraction of negative wells
at this input cell number was 100% (CTL estimate shown in figure as “10”).1828 Functionality of CTLs in HIV-infected Adults and Children
are included and show that the LDA method closely ap-
proximates the Elispot assay. These data strongly support
the hypothesis that a major factor contributing to the un-
derestimate of CTL numbers by use of the standard LDA is
the large input cell number per well which is adopted, and
not functionally inert cells.
Discussion
Use of peptide–MHC tetramers has revealed that even
higher levels of CTLs are present in response to acute and
chronic virus infections than was supposed previously (5,
25, 42, 43). An important potential explanation for the fail-
ure of the high-frequency HIV CTL response to control
HIV replication would be that a substantial portion of these
tetramer-staining CTLs are phenotypically silent. This phe-
nomenon has been clearly demonstrated in LCMV infec-
tion in mice (9, 10). However, the data shown here in
these studies argue against functionally inactive CTLs play-
ing a major role in either pediatric or adult chronic HIV
infection.
The conclusion that functionally inert CTLs are not
present in HIV infection is supported by numerous find-
ings. First, across a broad range of subjects studied, a very
close correlation exists between CTL numbers detectable
by tetramer and by Elispot (n 5 19, r 5 0.90) or intracellu-
lar IFN-g staining assays (n 5 29, r 5 0.97). The high cor-
relation between tetramer and the Elispot or intracellular
IFN-g staining assays was clearly present even in subjects
who had progressed to AIDS. This result is not compatible
with a disassociation between tetramer binding and IFN-g
release in response to antigen. Second, the level of tetramer
staining is strongly associated with the level of cytotoxicity
observed (r 5 0.79), as measured by detailed analysis of 50
LDA wells by tetramer staining. No wells were observed
that contained lymphocytes able to bind tetramer but inca-
pable of lytic activity. Third, modification of the LDA, us-
ing very low numbers of cells per well before in vitro cul-
ture, consistently and substantially increased the sensitivity
of the LDA to levels equivalent to those of the Elispot or
tetramer assay. This result implies that, given adequate
growth conditions, virtually every antigen-specific cell
placed in a PFA well has the capability to proliferate to a
level at which it is detectable in the chromium release assay
2–3 wk later. None of these results are consistent with phe-
notypically silent CTLs playing a substantial role in the
course of HIV infection in the 42 children and adults stud-
ied. Furthermore, these data are also fully consistent both
with those of Ogg et al. (6), who showed a strong negative
association between CTL numbers and HIV viral load in
chronically infected adults, and with the CD8 depletion
studies in SIV-infected macaques (7, 8), which directly
demonstrated the functionality of SIV-specific CTLs in
controlling viral load.
These studies, by the analysis of cells within LDA wells
using tetramers, have also highlighted the ease with which
standard LDAs can give underestimates of CTL numbers.
Direct evidence has shown that antigen-specific cells can be
overgrown by antigenically irrelevant cells. These data ex-
plain how the fraction of negative wells in one set of 24-
well replicates can be 4% if assayed at one time point, and
100% if assayed a few days later (as illustrated in Fig. 5).
However, at low input cell numbers per well these drastic
changes were not observed over time. It is interesting to
note that in a study of primary EBV infection, LDA per-
formed using autologous EBV-transformed B lymphoblas-
toid cell lines as feeders (37) gave very similar results to tet-
ramer staining subsequently performed (42). It is possible
that in this particular viral system, the potential for over-
growth by irrelevant T cells may be less of a problem.
These studies have relied mainly on PBMCs from
chronically infected children and adults, and it is quite pos-
sible that phenotypically silent CTLs may play a more sub-
stantial part during acute infection. It has been proposed
that perhaps ,1% of antigen-specific cells can proliferate
adequately in culture in acute virus infections (10), irre-
spective of competition for space from other cells. Whereas
massive Vb-specific and clonotypic expansions have been
demonstrated in acute HIV infection (44, 45), functional
CTL activity of a corresponding magnitude in general has
not been described (46, 47). Recent studies in acute hepati-
tis C infection suggest that CTLs may initially adopt a
“stunned” phenotype, unable to operate effectively and
soon to recover as viremia subsides (48). However, it is
worth noting than in one description of CTL responses in
acute HIV infection (16 d after the onset of symptoms), the
frequency of CTLs specific for an HLA-B44 Env epitope as
determined by the LDA demonstrated was as high as
62,500/106  PBMCs (49). Also, in the two B81 subjects an-
alyzed in this study soon after infection, 63 and 77% of B8
Nef tetramer–binding cells were detectable, respectively,
by intracellular IFN-g staining after stimulation of PBMCs
with the B8 Nef peptide (Table II). More extensive studies
of acutely infected subjects are clearly warranted and are
planned in this laboratory, pending the synthesis of the req-
uisite array of peptide–MHC tetramers.
It is possible that the CTL specificities that were not
tested in these studies may prove to lack functional activity
when analyzed similarly, as has been suggested by data both
from human T lymphocyte virus I infection (50) and HIV
infection (51; and Hay, M., unpublished data). Thus, it will
be important to extend these studies to include a more ex-
tensive coverage of the HIV-specific CTL responses that
are detectable than the four specificities described here.
The apparent low sensitivity of the LDA, as convention-
ally performed, has raised questions about the future useful-
ness of this assay. Even though the LDA can approach the
sensitivity of Elispot and tetramer assays when performed
under optimal conditions to allow proliferation of antigen-
specific cells of interest, as has been suggested by in vitro
expansion of low-frequency CTL clones sorted using tet-
ramers (52), it remains a much more labor-intensive assay
that has other significant disadvantages, including the use of
radioactivity. Epitope mapping by Elispot assay (53) and by
flow cytometric detection of intracellular IFN-g in re-
sponse to peptide stimulation (31, 41) is rapidly reducing1829 Goulder et al.
the value of CTL clones as a means of defining novel CTL
epitopes. However, the LDA remains a functional assay
that addresses the central cytotoxic activity of CTLs.
In conclusion, these data show that, in chronic pediatric
and adult HIV infection, phenotypically silent CTLs are
not a significant cause of persistence of virus in the face of
an apparently strong immune response. CTL numbers can
be reliably and conveniently estimated in HIV-1 infection
using Elispot assays, as Elispot and tetramer-derived estima-
tions correlate so closely (r 5 0.90). Intracellular IFN-g
staining of PBMCs by flow cytometry after peptide stimu-
lation provides an even closer estimate of CTL numbers to
that obtained by tetramer staining (r 5 0.97), and simulta-
neously allows immunophenotypic characterization of anti-
gen-specific cells. As a method, intracellular IFN-g staining
has greater flexibility, as synthesis of one tetramer per CTL
epitope is not practicable. LDAs can also be a reliable
method of quantifying CTLs, provided that conventional
methods for performing the assays are modified and only
low input cell numbers per well are used. However, LDAs
are not a consistent method of CTL enumeration when, as
is standard, high input cell numbers are used, as antigen-
specific cells of interest can be unpredictably overgrown by
antigenically irrelevant cells. Further comparison of CTL
numbers using LDA, tetramer, Elispot, and intracellular cy-
tokine staining assays will be of value in acute HIV infec-
tion, in which the relation between tetramer-binding cells
and functionality in those cells has not been established.
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